Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00500253 |
|
Recruitment Status : Unknown
Verified February 2013 by Iwona Stelmach, Medical Universtity of Lodz.
Recruitment status was: Recruiting
First Posted : July 12, 2007
Last Update Posted : February 7, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The aim of this study is to assess the utility of exhaled nitric oxide measurement (FeNO) in treatment monitoring in children with asthma.
According to the aim of the study following assumptions are formulated:
- Comparison of annual cumulative steroid dose, number of bronchodilator doses taken, number of asthma exacerbation, number of hospitalisation due to asthma, between group of children with asthma with FeNO monitored treatment (study group), and group of children with treatment monitored by GINA's grade of disease clinical control (control group)
- Assessment of corelation of FeNO (ppb) with symptom score (points)and lung function (FEV1)
- Comparison of values of non-specific bronchial hyperresponsiveness with methacholine (PC20M)between both study groups after 12. months of treatment.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Asthma | Device: exhaled nitric oxide measurement Procedure: bronchial hyperresponsiveness with methacholine (PC20M) Procedure: symptom score diary (according to 2007 GINA guidelines) | Phase 4 |
Asthma is one of the most common chronic disease worldwide, imposing a substantial social burden on both children and adults.
What needs to be kept in mind, especially in assessing treatment effect of allergic inflammation in children with asthma, is that symptom score and spirometry measures have limitations, mainly their subjectivity (symptom scores), wide variability, and lack of stability in short time period (symptom scores and spirometry measures).
Monitoring allergic inflammation in the course of asthma in children with exhaled nitric oxide measurement (FeNO) may allow to titrate the dose of inhaled glucocorticosteroids more precisely, depending on individual patients requirements.
The aim of this study is to assess the utility of FeNO in treatment monitoring in children with asthma.
According to the aim of the study following assumptions are formulated:
- Comparison of annual cumulative steroid dose, number of bronchodilator doses taken, number of asthma exacerbation, number of hospitalisation due to asthma, between group of children with asthma with FeNO monitored treatment (study group), and group of children with treatment monitored by GINA's grade of disease clinical control (control group)
- Assessment of corelation of FeNO (ppb) with symptom score (points)and lung function (FEV1)
- Comparison of values of non-specific bronchial hyperresponsiveness with methacholine (PC20M)between both study groups after 12. months of treatment.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 120 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Diagnostic |
| Official Title: | Assessment of Utility of Exhaled Nitric Oxide Measurement for Treatment Monitoring in Children With Asthma |
| Study Start Date : | February 2007 |
| Estimated Primary Completion Date : | November 2013 |
| Estimated Study Completion Date : | December 2013 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: 1
children with asthma with FeNO monitored treatment (study group)
|
Device: exhaled nitric oxide measurement
exhaled nitric oxide measurement
Other Name: exhaled nitric oxide measurement (Sievers FeNO analyzer) Procedure: bronchial hyperresponsiveness with methacholine (PC20M) bronchial hyperresponsiveness with methacholine (PC20M)
Other Name: PC20M Jaeger APS system |
|
2
group of children with treatment monitored by GINA's grade of disease clinical control (control group)
|
Procedure: bronchial hyperresponsiveness with methacholine (PC20M)
bronchial hyperresponsiveness with methacholine (PC20M)
Other Name: PC20M Jaeger APS system Procedure: symptom score diary (according to 2007 GINA guidelines) symptom score diary (according to 2007 GINA guidelines) |
- Control of the disease [ Time Frame: 1 year ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 6 Years to 18 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- FeNO values above the norm for age and inadequate asthma control (based GINA guidelines)
Exclusion Criteria:
- presence of other perennial and seasonal allergies
- presence of other chronic diseases
- excluded medications: systemic glucocorticosteroids 3 months before enrollment
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00500253
| Contact: Anna Sołoniewicz, MD | 00 48 42 6895972 | alergol@kopernik.lodz.pl |
| Poland | |
| Department of Pediatrics and Allergy, Medical University of Lodz, Lodz, Poland | Recruiting |
| Lodz, Poland, 93-513 | |
| Contact: Anna Sołoniewicz, MD 00 48 42 6895972 alergol@kopernik.lodz.pl | |
| Sub-Investigator: Anna Sołoniewicz, MD | |
| Principal Investigator: Iwona Stelmach, MD, PhD, Prof | |
| Principal Investigator: | Anna Sołoniewicz, MD | Department of Pediatrics and Allergy, Medical University of Lodz, Poland | |
| Study Chair: | Iwona Stelmach, MD, PhD, Prof | Department of Pediatrics and Allergy, Medical University of Lodz, Poland |
| Responsible Party: | Iwona Stelmach, MD, PhD, Professor, Medical Universtity of Lodz |
| ClinicalTrials.gov Identifier: | NCT00500253 History of Changes |
| Other Study ID Numbers: |
RNN-56-07-KE |
| First Posted: | July 12, 2007 Key Record Dates |
| Last Update Posted: | February 7, 2013 |
| Last Verified: | February 2013 |
Keywords provided by Iwona Stelmach, Medical Universtity of Lodz:
|
exhaled nitric oxide asthma children inhaled glucocorticosteroids |
Additional relevant MeSH terms:
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Nitric Oxide Methacholine Chloride Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs |
Anti-Asthmatic Agents Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Endothelium-Dependent Relaxing Factors Vasodilator Agents Gasotransmitters Protective Agents Miotics Parasympathomimetics Bronchoconstrictor Agents Muscarinic Agonists Cholinergic Agonists |